Guggenheim Capital LLC Sells 36,855 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Guggenheim Capital LLC reduced its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 33.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 74,952 shares of the biotechnology company's stock after selling 36,855 shares during the period. Guggenheim Capital LLC's holdings in Exelixis were worth $2,496,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Tri Ri Asset Management Corp bought a new stake in Exelixis during the 3rd quarter worth approximately $4,396,000. Blue Trust Inc. boosted its holdings in shares of Exelixis by 134.7% in the fourth quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock valued at $476,000 after buying an additional 8,208 shares during the period. Range Financial Group LLC bought a new stake in shares of Exelixis during the fourth quarter worth $994,000. Raymond James Financial Inc. acquired a new stake in shares of Exelixis during the fourth quarter worth $17,046,000. Finally, Allspring Global Investments Holdings LLC lifted its position in Exelixis by 82.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,562,790 shares of the biotechnology company's stock valued at $52,884,000 after acquiring an additional 704,786 shares in the last quarter. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Performance

Shares of EXEL stock traded up $0.43 during midday trading on Thursday, hitting $37.21. 1,736,232 shares of the company were exchanged, compared to its average volume of 2,176,361. The firm has a market capitalization of $10.41 billion, a P/E ratio of 21.02, a PEG ratio of 1.13 and a beta of 0.57. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.02. The firm's 50 day moving average price is $36.57 and its two-hundred day moving average price is $34.45.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on EXEL shares. Stifel Nicolaus upped their price objective on Exelixis from $30.00 to $36.00 and gave the stock a "hold" rating in a research report on Wednesday, February 12th. Stephens reaffirmed an "equal weight" rating and set a $29.00 price target on shares of Exelixis in a research report on Wednesday, February 12th. Citigroup raised their price target on shares of Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a research note on Wednesday, February 12th. Barclays boosted their price objective on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Thursday, February 13th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 target price on shares of Exelixis in a research report on Thursday, March 27th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $37.59.

Insiders Place Their Bets

In related news, CFO Christopher J. Senner sold 29,314 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now directly owns 779,607 shares in the company, valued at approximately $28,174,996.98. The trade was a 3.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Patrick J. Haley sold 52,636 shares of Exelixis stock in a transaction on Monday, February 24th. The shares were sold at an average price of $36.98, for a total value of $1,946,479.28. Following the completion of the transaction, the executive vice president now directly owns 303,310 shares of the company's stock, valued at $11,216,403.80. This represents a 14.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 140,343 shares of company stock worth $5,177,234 in the last 90 days. Company insiders own 2.85% of the company's stock.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.